Chayanupatkul Maneerat, Liangpunsakul Suthat
Maneerat Chayanupatkul, Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, United States.
World J Gastroenterol. 2014 May 28;20(20):6279-86. doi: 10.3748/wjg.v20.i20.6279.
Alcoholic hepatitis (AH) is an acute hepatic inflammation associated with significant morbidity and mortality. Current evidence suggests that the pathogenesis is the end result of the complex interplay between ethanol metabolism, inflammation and innate immunity. Several clinical scoring systems have been derived to predict the clinical outcomes of patients with AH; such as Child-Turcotte-Pugh score, the Maddrey discriminant function, the Lille Model, the model for end stage liver disease scores, and the Glasgow alcoholic hepatitis score. At present, Corticosteroids or pentoxifylline are the current pharmacologic treatment options; though the outcomes from the therapies are poor. Liver transplantation as the treatment of alcoholic hepatitis remains controversial, and in an era of organ shortage current guidelines do not recommend transplantation as the treatment option. Because of the limitations in the therapeutic options, it is no doubt that there is a critical need for the newer and more effective pharmacological agents to treat AH.
酒精性肝炎（AH）是一种急性肝脏炎症，伴有显著的发病率和死亡率。目前的证据表明，其发病机制是乙醇代谢、炎症和固有免疫之间复杂相互作用的最终结果。已经得出了几种临床评分系统来预测AH患者的临床结局；如Child-Turcotte-Pugh评分、Maddrey判别函数、里尔模型、终末期肝病模型评分以及格拉斯哥酒精性肝炎评分。目前，皮质类固醇或己酮可可碱是当前的药物治疗选择；尽管这些疗法的效果不佳。肝移植作为酒精性肝炎的治疗方法仍存在争议，在器官短缺的时代，当前指南不推荐将移植作为治疗选择。由于治疗选择存在局限性，毫无疑问，迫切需要更新、更有效的药物来治疗AH。
